Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 19Neoplasm Metastasis 5Triple Negative Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2HER2-positive Breast Cancer 2Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumor 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Gemcitabine 2selinexor 1ponatinib 1neratinib 1folfirinox 1contrast agent BR1 1cobimetinib 1ceritinib 1brigatinib 1abemaciclib 1Urination 1S 1 (combination) 1Radiotherapy 1Radiosurgery 1Practice Guidelines as Topic 1Pancreaticoduodenectomy 1Paclitaxel 1Oxaliplatin 1Long Interspersed Nucleotide Elements 1Laparoscopy 1Irinotecan 1Immunotherapy, Adoptive 1Floxuridine 1Etoposide 1Endosonography 1Endoscopic Ultrasound-Guided Fine Needle Aspiration 1Drug Therapy 1Doxorubicin 1Colchicine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Pancreatic Ductal × neratinib × Clear all
NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

University Health Network, Toronto

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡